Zura Bio Limited Class A Ordinary Shares ZURA · Stock Open Zura Bio Limited Class A Ordinary Shares in new tab
Zura Bio Limited Class A Ordinary Shares Analysis (ZURA)
Is Zura Bio Limited Class A Ordinary Shares a good investment? Zura Bio Limited Class A Ordinary Shares (ZURA) is currently trading at 4.14 USD. Market analysts have a consensus price target of 18.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Zura Bio Limited Class A Ordinary Shares is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.58.
Investor FAQ
Does Zura Bio Limited Class A Ordinary Shares pay a dividend?
No, it does not currently pay a dividend.
What asset class is Zura Bio Limited Class A Ordinary Shares?
Zura Bio Limited Class A Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.09.
Company Profile
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Community Discussion